Penserra Capital Management LLC Makes New $2.35 Million Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Penserra Capital Management LLC purchased a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) during the 3rd quarter, Holdings Channel reports. The institutional investor purchased 117,581 shares of the biotechnology company’s stock, valued at approximately $2,350,000.

A number of other hedge funds have also recently added to or reduced their stakes in ADMA. Assenagon Asset Management S.A. lifted its position in shares of ADMA Biologics by 2.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock worth $69,454,000 after buying an additional 92,281 shares during the last quarter. Seven Eight Capital LP acquired a new stake in ADMA Biologics during the second quarter worth about $1,992,000. Principal Financial Group Inc. lifted its holdings in ADMA Biologics by 785.7% in the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock worth $23,872,000 after acquiring an additional 1,059,394 shares during the last quarter. Louisiana State Employees Retirement System acquired a new position in ADMA Biologics in the third quarter valued at approximately $2,253,000. Finally, Point72 Asset Management L.P. bought a new position in shares of ADMA Biologics during the second quarter valued at approximately $1,157,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the transaction, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $16.90, for a total value of $408,135.00. Following the completion of the sale, the chief operating officer now directly owns 449,088 shares in the company, valued at $7,589,587.20. This represents a 5.10 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 185,011 shares of company stock valued at $3,255,204. Company insiders own 3.70% of the company’s stock.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $21.47 on Tuesday. ADMA Biologics, Inc. has a 12-month low of $3.60 and a 12-month high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The firm has a market capitalization of $5.08 billion, a price-to-earnings ratio of 76.68 and a beta of 0.64. The business has a 50 day simple moving average of $18.86 and a 200 day simple moving average of $14.95.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. During the same quarter in the prior year, the business posted $0.01 earnings per share. On average, equities research analysts anticipate that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price objective on shares of ADMA Biologics in a research report on Friday, September 20th. Raymond James boosted their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. Finally, HC Wainwright upped their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.